Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00338130 · ClinicalTrials.gov registry record · Phase 2
Randomised Study to Compare the Efficacy of AZD6244 vs TMZ
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 239
- Enrollment target
NCT00338130 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 239 participants.
The verdict
NCT00338130, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 239 participants
- Enrollment target
Study Summary
The primary purpose of this study is to compare the efficacy of AZD6244 (ARRY-142886) with temozolomide in patients with advanced melanoma
Interventions
- DRUG Temozolomide
- DRUG AZD6244
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2006-07 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00338130
The ClinicalTrials.gov registry entry for NCT00338130 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Temozolomide is the first listed.
NCT00338130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00338130 about?
NCT00338130 is a clinical study titled "Randomised Study to Compare the Efficacy of AZD6244 vs TMZ". The primary purpose of this study is to compare the efficacy of AZD6244 (ARRY-142886) with temozolomide in patients with advanced melanoma
What is the current status of trial NCT00338130?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 239 participants. The study started on 2006-07. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00338130?
The interventions under investigation include: Temozolomide (DRUG), AZD6244 (DRUG).
Who is sponsoring clinical trial NCT00338130?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.